Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Preclinical Evaluation of the Versius Surgical System, a New Robot-assisted Surgical Device for Use in Minimal Access Renal and Prostate Surgery.

Thomas BC, Slack M, Hussain M, Barber N, Pradhan A, Dinneen E, Stewart GD.

Eur Urol Focus. 2020 Mar 10. pii: S2405-4569(20)30029-8. doi: 10.1016/j.euf.2020.01.011. [Epub ahead of print]

2.

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.

Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger AL, Chandrananda D, Heider K, Wan JCM, Warren AY, Morris J, Hudecova I, Cooper WN, Mitchell TJ, Gale D, Ruiz-Valdepenas A, Klatte T, Ursprung S, Sala E, Riddick ACP, Aho TF, Armitage JN, Perakis S, Pichler M, Seles M, Wcislo G, Welsh SJ, Matakidou A, Eisen T, Massie CE, Rosenfeld N, Heitzer E, Stewart GD.

Genome Med. 2020 Feb 28;12(1):23. doi: 10.1186/s13073-020-00723-8.

3.

Re: Transcriptomic Signatures Related to the Obesity Paradox in Patients with Clear Cell Renal Cell Carcinoma: A Cohort Study.

Yong C, Stewart GD.

Eur Urol. 2020 Feb 12. pii: S0302-2838(20)30069-5. doi: 10.1016/j.eururo.2020.01.031. [Epub ahead of print] No abstract available.

PMID:
32061449
4.

Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma-a systematic review and meta-analysis.

Ursprung S, Beer L, Bruining A, Woitek R, Stewart GD, Gallagher FA, Sala E.

Eur Radiol. 2020 Feb 14. doi: 10.1007/s00330-020-06666-3. [Epub ahead of print]

PMID:
32060715
5.

Partial nephrectomy versus thermal ablation for clinical T1 renal tumours.

Klatte T, Stewart GD.

Ann Transl Med. 2019 Dec;7(Suppl 8):S363. doi: 10.21037/atm.2019.09.12. No abstract available.

6.

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J, Klatte T, Staehler M, Powles T, Bex A.

Eur Urol Oncol. 2020 Jan 16. pii: S2588-9311(20)30001-8. doi: 10.1016/j.euo.2019.12.004. [Epub ahead of print]

PMID:
31956080
7.

The influence of hypoxia on the prostate cancer proteome.

Ross JA, Vissers JPC, Nanda J, Stewart GD, Husi H, Habib FK, Hammond DE, Gethings LA.

Clin Chem Lab Med. 2020 Jan 15. pii: /j/cclm.ahead-of-print/cclm-2019-0626/cclm-2019-0626.xml. doi: 10.1515/cclm-2019-0626. [Epub ahead of print]

PMID:
31940282
8.

Immunohistochemistry as a tool for screening rare renal cancers.

Yong C, Stewart GD, Frezza C.

Ann Transl Med. 2019 Dec;7(Suppl 8). pii: S314. doi: 10.21037/atm.2019.10.18. No abstract available.

9.

Embryonal precursors of Wilms tumor.

Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB, Mitchell TJ, Tugnait S, Thevanesan C, Young MD, Oliver TRW, Oostveen M, Collord G, Tarpey PS, Cagan A, Hooks Y, Brougham M, Reynolds BC, Barone G, Anderson J, Jorgensen M, Burke GAA, Visser J, Nicholson JC, Smeulders N, Mushtaq I, Stewart GD, Campbell PJ, Wedge DC, Martincorena I, Rampling D, Hook L, Warren AY, Coleman N, Chowdhury T, Sebire N, Drost J, Saeb-Parsy K, Stratton MR, Straathof K, Pritchard-Jones K, Behjati S.

Science. 2019 Dec 6;366(6470):1247-1251. doi: 10.1126/science.aax1323.

10.

UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time.

Vasudev NS, Hutchinson M, Trainor S, Ferguson R, Bhattarai S, Adeyoju A, Cartledge J, Kimuli M, Datta S, Hanbury D, Hrouda D, Oades G, Patel P, Soomro N, Stewart GD, Sullivan M, Webster J, Messenger M, Selby PJ, Banks RE.

Urology. 2020 Feb;136:162-168. doi: 10.1016/j.urology.2019.09.044. Epub 2019 Nov 6.

11.

A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain.

Ramírez-García PD, Retamal JS, Shenoy P, Imlach W, Sykes M, Truong N, Constandil L, Pelissier T, Nowell CJ, Khor SY, Layani LM, Lumb C, Poole DP, Lieu T, Stewart GD, Mai QN, Jensen DD, Latorre R, Scheff NN, Schmidt BL, Quinn JF, Whittaker MR, Veldhuis NA, Davis TP, Bunnett NW.

Nat Nanotechnol. 2019 Dec;14(12):1150-1159. doi: 10.1038/s41565-019-0568-x. Epub 2019 Nov 4.

PMID:
31686009
12.

Oncometabolites in renal cancer.

Yong C, Stewart GD, Frezza C.

Nat Rev Nephrol. 2020 Mar;16(3):156-172. doi: 10.1038/s41581-019-0210-z. Epub 2019 Oct 21. Review.

13.

Spatiotemporal immune zonation of the human kidney.

Stewart BJ, Ferdinand JR, Young MD, Mitchell TJ, Loudon KW, Riding AM, Richoz N, Frazer GL, Staniforth JUL, Vieira Braga FA, Botting RA, Popescu DM, Vento-Tormo R, Stephenson E, Cagan A, Farndon SJ, Polanski K, Efremova M, Green K, Del Castillo Velasco-Herrera M, Guzzo C, Collord G, Mamanova L, Aho T, Armitage JN, Riddick ACP, Mushtaq I, Farrell S, Rampling D, Nicholson J, Filby A, Burge J, Lisgo S, Lindsay S, Bajenoff M, Warren AY, Stewart GD, Sebire N, Coleman N, Haniffa M, Teichmann SA, Behjati S, Clatworthy MR.

Science. 2019 Sep 27;365(6460):1461-1466. doi: 10.1126/science.aat5031.

PMID:
31604275
14.

The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.

Klatte T, Gallagher KM, Afferi L, Volpe A, Kroeger N, Ribback S, McNeill A, Riddick ACP, Armitage JN, 'Aho TF, Eisen T, Fife K, Bex A, Pantuck AJ, Stewart GD.

BMC Med. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1.

15.

A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound.

Rossi SH, Klatte T, Usher-Smith JA, Fife K, Welsh SJ, Dabestani S, Bex A, Nicol D, Nathan P, Stewart GD, Wilson ECF.

Eur Urol Focus. 2019 Sep 14. pii: S2405-4569(19)30277-9. doi: 10.1016/j.euf.2019.09.002. [Epub ahead of print]

PMID:
31530498
16.

Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer.

Rossi SH, Blick C, Nathan P, Nicol D, Stewart GD, Wilson ECF.

Value Health. 2019 Sep;22(9):981-987. doi: 10.1016/j.jval.2019.03.018. Epub 2019 May 31.

PMID:
31511187
17.

Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, Brugarolas J, Chen YB, Linehan WM, Maher ER, Merino MJ, Offit K, Reuter VE, Shuch B, Coleman JA.

Eur Urol. 2019 Dec;76(6):754-764. doi: 10.1016/j.eururo.2019.06.015. Epub 2019 Jul 18. Review.

PMID:
31326218
18.

Guideline adherence for the surgical treatment of T1 renal tumours correlates with hospital volume: an analysis from the British Association of Urological Surgeons Nephrectomy Audit.

Tran MGB, Aben KKH, Werkhoven E, Neves JB, Fowler S, Sullivan M, Stewart GD, Challacombe B, Mahrous A, Patki P, Mumtaz F, Barod R, Bex A; British Association of Urological Surgeons.

BJU Int. 2020 Jan;125(1):73-81. doi: 10.1111/bju.14862. Epub 2019 Aug 18.

PMID:
31293036
19.

Disagreement in risk groups for metastatic renal cancer.

Klatte T, Stewart GD.

Nat Rev Urol. 2019 Jun;16(6):332-333. doi: 10.1038/s41585-019-0174-6. No abstract available.

PMID:
30911153
20.

Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care.

Rossi SH, Fielding A, Blick C, Handforth C, Brown JE, Stewart GD.

Eur Urol. 2019 Jun;75(6):891-893. doi: 10.1016/j.eururo.2019.03.008. Epub 2019 Mar 23.

21.

Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Scand J Urol. 2019 Feb;53(1):14-20. doi: 10.1080/21681805.2019.1588919. Epub 2019 Mar 25.

PMID:
30907214
22.

A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma.

Syafruddin SE, Rodrigues P, Vojtasova E, Patel SA, Zaini MN, Burge J, Warren AY, Stewart GD, Eisen T, Bihary D, Samarajiwa SA, Vanharanta S.

Nat Commun. 2019 Mar 11;10(1):1152. doi: 10.1038/s41467-019-09116-x.

23.

Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement.

Rossi SH, Blick C, Handforth C, Brown JE, Stewart GD; Renal Cancer Gap Analysis Collaborative.

Eur Urol Focus. 2019 Feb 14. pii: S2405-4569(19)30016-1. doi: 10.1016/j.euf.2019.01.014. [Epub ahead of print]

PMID:
30772357
24.

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA.

Int J Mol Sci. 2018 Dec 2;19(12). pii: E3837. doi: 10.3390/ijms19123837. Review.

25.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

26.

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol. 2019 Feb;75(2):261-264. doi: 10.1016/j.eururo.2018.10.007. Epub 2018 Oct 11.

PMID:
30318330
27.

Renal cell carcinoma: standards and controversies.

Klatte T, Stewart GD.

World J Urol. 2018 Dec;36(12):1889-1890. doi: 10.1007/s00345-018-2490-5. No abstract available.

PMID:
30209553
28.

Genomics and clinical correlates of renal cell carcinoma.

Mitchell TJ, Rossi SH, Klatte T, Stewart GD.

World J Urol. 2018 Dec;36(12):1899-1911. doi: 10.1007/s00345-018-2429-x. Epub 2018 Aug 11. Review.

29.

Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors.

Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ, Ferdinand JR, Collord G, Botting RA, Popescu DM, Loudon KW, Vento-Tormo R, Stephenson E, Cagan A, Farndon SJ, Del Castillo Velasco-Herrera M, Guzzo C, Richoz N, Mamanova L, Aho T, Armitage JN, Riddick ACP, Mushtaq I, Farrell S, Rampling D, Nicholson J, Filby A, Burge J, Lisgo S, Maxwell PH, Lindsay S, Warren AY, Stewart GD, Sebire N, Coleman N, Haniffa M, Teichmann SA, Clatworthy M, Behjati S.

Science. 2018 Aug 10;361(6402):594-599. doi: 10.1126/science.aat1699.

30.

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A.

World J Urol. 2018 Dec;36(12):1973-1980. doi: 10.1007/s00345-018-2427-z. Epub 2018 Aug 1.

PMID:
30069581
31.

Quality of life outcomes in patients with localised renal cancer: a literature review.

Rossi SH, Klatte T, Stewart GD.

World J Urol. 2018 Dec;36(12):1961-1972. doi: 10.1007/s00345-018-2415-3. Epub 2018 Jul 26. Review.

32.

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT.

Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.

Southampton (UK): NIHR Journals Library; 2018 Jun.

33.

NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis.

Rodrigues P, Patel SA, Harewood L, Olan I, Vojtasova E, Syafruddin SE, Zaini MN, Richardson EK, Burge J, Warren AY, Stewart GD, Saeb-Parsy K, Samarajiwa SA, Vanharanta S.

Cancer Discov. 2018 Jul;8(7):850-865. doi: 10.1158/2159-8290.CD-17-1211. Epub 2018 Jun 6.

34.

Prognostic factors and prognostic models for renal cell carcinoma: a literature review.

Klatte T, Rossi SH, Stewart GD.

World J Urol. 2018 Dec;36(12):1943-1952. doi: 10.1007/s00345-018-2309-4. Epub 2018 Apr 30. Review.

PMID:
29713755
35.

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, Butler AP, Raine K, Stewart GD, Challacombe B, Fernando A, Lopez JI, Hazell S, Chandra A, Chowdhury S, Rudman S, Soultati A, Stamp G, Fotiadis N, Pickering L, Au L, Spain L, Lynch J, Stares M, Teague J, Maura F, Wedge DC, Horswell S, Chambers T, Litchfield K, Xu H, Stewart A, Elaidi R, Oudard S, McGranahan N, Csabai I, Gore M, Futreal PA, Larkin J, Lynch AG, Szallasi Z, Swanton C, Campbell PJ; TRACERx Renal Consortium.

Cell. 2018 Apr 19;173(3):611-623.e17. doi: 10.1016/j.cell.2018.02.020. Epub 2018 Apr 12.

36.

Epidemiology and screening for renal cancer.

Rossi SH, Klatte T, Usher-Smith J, Stewart GD.

World J Urol. 2018 Sep;36(9):1341-1353. doi: 10.1007/s00345-018-2286-7. Epub 2018 Apr 2. Review.

37.

Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol Focus. 2019 Sep;5(5):857-866. doi: 10.1016/j.euf.2018.02.010. Epub 2018 Mar 7.

PMID:
29525381
38.

Allosteric interactions between GABAB1 subunits control orthosteric binding sites occupancy within GABAB oligomers.

Stewart GD, Comps-Agrar L, Nørskov-Lauritsen LB, Pin JP, Kniazeff J.

Neuropharmacology. 2018 Jul 1;136(Pt A):92-101. doi: 10.1016/j.neuropharm.2017.12.042. Epub 2018 Jan 2.

39.

Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.

Klatte T, Fife K, Welsh SJ, Sachdeva M, Armitage JN, 'Aho T, Riddick AC, Matakidou A, Eisen T, Stewart GD.

World J Urol. 2018 Mar;36(3):417-425. doi: 10.1007/s00345-017-2154-x. Epub 2017 Dec 18.

PMID:
29256020
40.

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Figlin RA, Leibovich BC, Stewart GD, Negrier S.

Ann Oncol. 2018 Feb 1;29(2):324-331. doi: 10.1093/annonc/mdx743. Review.

41.

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

Stewart GD, Leibovich BC, Negrier S, Figlin RA.

J Clin Oncol. 2017 Dec 10;35(35):3895-3897. doi: 10.1200/JCO.2017.75.4242. Epub 2017 Oct 25. No abstract available.

PMID:
29068785
42.

Management of a Renal Mass in a Solitary Kidney: To Freeze or To Cut?

Klatte T, Riddick ACP, Stewart GD.

Eur Urol. 2018 Feb;73(2):260-261. doi: 10.1016/j.eururo.2017.09.023. Epub 2017 Oct 9. No abstract available.

PMID:
29032847
43.

Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.

Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, Andrews KA, Roberts T, Clark GR, West H, Smith PS, Docquier FM, Rodger F, Murray V, Simpson HL, Wallis Y, Giger O, Tran M, Tomkins S, Stewart GD, Park SM, Woodward ER, Maher ER.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4013-4022. doi: 10.1210/jc.2017-00562. Review.

44.

Quantitative mechanical assessment of the whole prostate gland ex vivo using dynamic instrumented palpation.

Hammer SJ, Good DW, Scanlan P, Palacio-Torralba J, Phipps S, Stewart GD, Shu W, Chen Y, McNeill SA, Reuben RL.

Proc Inst Mech Eng H. 2017 Dec;231(12):1081-1100. doi: 10.1177/0954411917734257. Epub 2017 Sep 30.

PMID:
28965486
45.

European temporal trends in the use of lymph node dissection in patients with renal cancer.

Capitanio U, Stewart GD, Larcher A, Ouzaid I, Akdogan B, Roscigno M, Marszalek M, Dell'Oglio P, Salagierski M, Volpe A, Mir MC, Kriegmair M, Terrone C, Brookman-May SD, Montorsi F, Klatte T; Kidney Cancer Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU).

Eur J Surg Oncol. 2017 Nov;43(11):2184-2192. doi: 10.1016/j.ejso.2017.07.016. Epub 2017 Aug 3.

PMID:
28801061
46.

Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.

Blick C, Ritchie AWS, Eisen T, Stewart GD.

Nat Rev Urol. 2017 Dec;14(12):753-759. doi: 10.1038/nrurol.2017.123. Epub 2017 Aug 1. Review.

PMID:
28762388
47.

Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?

Capitanio U, Stewart GD, Klatte T, Akdogan B, Roscigno M, Marszalek M, Dell'Oglio P, Zaffuto E, Rodriguez Faba O, Salagierski M, Lingard J, Carini M, Ouzaid I, Mir MC, Montorsi F, Da Pozzo LF, Stief C, Minervini A, Brookman-May SD.

Eur Urol Focus. 2018 Dec;4(6):972-977. doi: 10.1016/j.euf.2017.02.020. Epub 2017 Mar 21.

PMID:
28753867
48.

A novel method for rapid and quantitative mechanical assessment of soft tissue for diagnostic purposes: A computational study.

Palacio-Torralba J, Good DW, Stewart GD, McNeill SA, Reuben RL, Chen Y.

Int J Numer Method Biomed Eng. 2018 Feb;34(2). doi: 10.1002/cnm.2917. Epub 2017 Aug 23.

49.

Immunotherapy for Renal Cancer: Sequencing and Combinations.

Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G.

Eur Urol Focus. 2016 Dec 15;2(6):582-588. doi: 10.1016/j.euf.2017.04.002. Epub 2017 Apr 20. Review.

PMID:
28723489
50.

Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer.

Lubbock ALR, Stewart GD, O'Mahony FC, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ, Overton IM.

BMC Med. 2017 Jun 26;15(1):118. doi: 10.1186/s12916-017-0874-9.

Supplemental Content

Loading ...
Support Center